ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1124

Total Knee Replacement As an Osteoarthritis Study Outcome: Predictors Derived From Long-Term Observation Following a Randomized Clinical Trial

Jean-Pierre Raynauld1, Johanne Martel-Pelletier1, Marc Dorais2, Boulos Haraoui1, Denis Choquette1, François Abram3, André Beaulieu4, Louis Bessette5, Frédéric Morin6, Lukas M. Wildi1 and Jean Pierre Pelletier7, 1Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, 2StatSciences Inc., Notre-Dame de l’Île Perrot, QC, Canada, 3Medical Imaging Research & Development, ArthroLab Inc., Montreal, QC, Canada, 4Faculty of Medicine, Laval University, Quebec, QC, Canada, 5Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, 6Centre de Recherche Musculo-squelettique, Trois-Rivières, QC, Canada, 7Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: chondroitin, Knee, Magnetic resonance imaging (MRI), osteoarthritis and total joint replacement

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoarthritis - Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: Using data from a 4-year follow-up of knee OA patients who formerly received treatment with chondroitin sulfate (CS) within a 6-month clinical trial, we wanted to find predictors of the incidence of total knee replacement (TKR).

Methods: Knee OA patients participating in a randomized, double-blind controlled trial evaluating the impact of CS (Bioibérica S.A., Barcelona, Spain) (400 mg BID) vs. placebo who had serial MRI acquisitions (qMRI) and clinical evaluations of the symptomatic knee[1] were contacted to evaluate retrospectively the incidence of TKR of the study knee. A sub-group of patients (n=57) who received the study medication and had all the MRI evaluations (intent to treat (ITT)) were selected for this post hoc retrospective analysis. The TKR incidence was assessed blindly to the treatment allocation with a standardized phone interview.

Results: The patients’ mean age was 63.2 years, 63% were female and the average body mass index (BMI) was 30.7 kg¨Mm2. A total of 13 TKRs (22.8%) were performed on this sub-population in the time frame of 4 years after completion of the original study. Interestingly, there were more TKRs performed within the placebo group (n=9) than the CS group (n=4) (69% vs. 31%, p=0.15, logistic regression). We further investigated the predictors of long-term TKRs for the target knee by comparing, within the ITT cohort, the patients who had TKR (n=13) for the target knee to those who did not (n=44), using data at baseline or the change at 1 year. Baseline values of WOMAC pain (p=0.01, logistic regression) and function (p=0.04), bone marrow lesions (BMLs) in the medial tibial plateau (p=0.0008) and global knee (0.02), and C-reactive protein (CRP) level (p=0.05) were strong predictors of TKR. Changes at 1 year in the medial cartilage volume higher than 7% (p=0.03) and the change in WOMAC pain (p=0.02) and function (p=0.02) also predicted the occurrence of TKR. Multivariate analyses controlling for age, sex, and BMI revealed that baseline presence of BML (p=0.003) and WOMAC pain (p=0.006) were independent strong predictors of TKR. Time to occurrence of the TKR from the study inception also favored the CS group vs. placebo (Log-Rank, p=0.14). Cox regressions that included age, sex, and BMI in the model indicated that baseline values of WOMAC pain (p=0.0006), presence of BML in the medial compartment (p=0.0007) and CRP (p=0.02) were the strongest independent predictors of TKR over time.

Conclusion: Treatment with CS appeared to reduce the need for TKR. There are very few OA RCTs that use qMRI to probe knee structural outcomes. According to this study, predictors of long-term occurrence of a TKR were greater levels of knee pain, lower level of function and presence of BML at baseline, and greater loss of cartilage over time. This study links MRI findings to long-term clinical outcomes.

Reference: [1] Wildi LM, et al. Ann Rheum Dis 2011;70(6):982-9


Disclosure:

J. P. Raynauld,

ArthroLab Inc.,

4;

J. Martel-Pelletier,

ArthroLab Inc.,

4,

Bioibérica S.A.,

5;

M. Dorais,

ArthroLab Inc.,

5;

B. Haraoui,

ArthroLab Inc.,

9;

D. Choquette,

ArthroLab Inc.,

9;

F. Abram,

ArthroLab Inc.,

3;

A. Beaulieu,

ArthroLab Inc.,

9;

L. Bessette,

ArthroLab Inc.,

9;

F. Morin,

ArthroLab Inc.,

9;

L. M. Wildi,
None;

J. P. Pelletier,

ArthroLab Inc.,

4,

Bioibérica S.A.,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/total-knee-replacement-as-an-osteoarthritis-study-outcome-predictors-derived-from-long-term-observation-following-a-randomized-clinical-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology